company background image
CURR

CURE Pharmaceutical Holding OTCPK:CURR Stock Report

Last Price

US$0.34

Market Cap

US$23.8m

7D

30.5%

1Y

-39.3%

Updated

06 Aug, 2022

Data

Company Financials
CURR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

CURR Stock Overview

CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence.

CURE Pharmaceutical Holding Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CURE Pharmaceutical Holding
Historical stock prices
Current Share PriceUS$0.34
52 Week HighUS$0.85
52 Week LowUS$0.18
Beta0.58
1 Month Change0.15%
3 Month Change3.03%
1 Year Change-39.29%
3 Year Change-91.54%
5 Year Change-94.93%
Change since IPO-83.41%

Recent News & Updates

Shareholder Returns

CURRUS PharmaceuticalsUS Market
7D30.5%-3.0%1.0%
1Y-39.3%1.9%-12.9%

Return vs Industry: CURR underperformed the US Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: CURR underperformed the US Market which returned -12.8% over the past year.

Price Volatility

Is CURR's price volatile compared to industry and market?
CURR volatility
CURR Average Weekly Movement21.4%
Pharmaceuticals Industry Average Movement11.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: CURR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: CURR's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201124Rob Davidsonhttps://www.curepharmaceutical.com

CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company’s pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety.

CURE Pharmaceutical Holding Fundamentals Summary

How do CURE Pharmaceutical Holding's earnings and revenue compare to its market cap?
CURR fundamental statistics
Market CapUS$23.75m
Earnings (TTM)-US$15.17m
Revenue (TTM)US$6.21m

3.8x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CURR income statement (TTM)
RevenueUS$6.21m
Cost of RevenueUS$2.11m
Gross ProfitUS$4.10m
Other ExpensesUS$19.28m
Earnings-US$15.17m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin66.05%
Net Profit Margin-244.21%
Debt/Equity Ratio127.0%

How did CURR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CURR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CURR?

Other financial metrics that can be useful for relative valuation.

CURR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.3x
Enterprise Value/EBITDA-3.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CURR's PS Ratio compare to its peers?

CURR PS Ratio vs Peers
The above table shows the PS ratio for CURR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average16.2x
AYTU Aytu BioPharma
0.2x9.3%US$21.6m
ACER Acer Therapeutics
62.4x195.2%US$22.5m
LVRL.F CordovaCann
1.8xn/aUS$19.1m
VYNE VYNE Therapeutics
1.6x77.3%US$24.1m
CURR CURE Pharmaceutical Holding
3.8xn/aUS$23.8m

Price-To-Sales vs Peers: CURR is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (16.2x).


Price to Earnings Ratio vs Industry

How does CURR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: CURR is good value based on its Price-To-Sales Ratio (3.8x) compared to the US Pharmaceuticals industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is CURR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CURR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CURR's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CURR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CURR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CURR's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is CURE Pharmaceutical Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CURE Pharmaceutical Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of CURR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access CURE Pharmaceutical Holding's filings and announcements here.

Past Performance

How has CURE Pharmaceutical Holding performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CURR is currently unprofitable.

Growing Profit Margin: CURR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CURR is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.

Accelerating Growth: Unable to compare CURR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).


Return on Equity

High ROE: CURR has a negative Return on Equity (-125.41%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is CURE Pharmaceutical Holding's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CURR's short term assets ($2.3M) do not cover its short term liabilities ($25.1M).

Long Term Liabilities: CURR's short term assets ($2.3M) exceed its long term liabilities ($165.0K).


Debt to Equity History and Analysis

Debt Level: CURR's net debt to equity ratio (122.6%) is considered high.

Reducing Debt: CURR's debt to equity ratio has increased from 4.4% to 127% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CURR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CURR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.5% each year


Discover healthy companies

Dividend

What is CURE Pharmaceutical Holding current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CURR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CURR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CURR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CURR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.2yrs

Average management tenure


CEO

Rob Davidson (55 yo)

11.08yrs

Tenure

US$600,652

Compensation

Mr. Robert Davidson, also known as Rob, serves as Chief Executive Officer and Director of CURE Pharmaceutical Holding Corp since July 2011 and serves as its President since January 2019. He served as Chair...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD600.65K) is about average for companies of similar size in the US market ($USD767.72K).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CURR's management team is seasoned and experienced (7.2 years average tenure).


Board Members

Experienced Board: CURR's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CURE Pharmaceutical Holding Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: CURE Pharmaceutical Holding Corp.
  • Ticker: CURR
  • Exchange: OTCPK
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$23.755m
  • Shares outstanding: 69.87m
  • Website: https://www.curepharmaceutical.com

Number of Employees


Location

  • CURE Pharmaceutical Holding Corp.
  • 1620 Beacon Place
  • Oxnard
  • California
  • 93033
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.